These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 1849042)
1. Pharmacokinetic and preliminary metabolic fate of navelbine in humans as determined by high performance liquid chromatography. Jehl F; Quoix E; Leveque D; Pauli G; Breillout F; Krikorian A; Monteil H Cancer Res; 1991 Apr; 51(8):2073-6. PubMed ID: 1849042 [TBL] [Abstract][Full Text] [Related]
2. The clinical pharmacokinetics of vinorelbine (Navelbine). Wargin WA; Lucas VS Semin Oncol; 1994 Oct; 21(5 Suppl 10):21-7. PubMed ID: 7973765 [TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics of vinorelbine alone and combined with cisplatin. Levêque D; Jehl F; Quoix E; Breillout F J Clin Pharmacol; 1992 Dec; 32(12):1096-8. PubMed ID: 1336784 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic profile of vinorelbine, a new semi-synthetic vinca alkaloid, determined by high-performance liquid chromatography. Levêque D; Jehl F; Quoix E; Monteil H Xenobiotica; 1993 Nov; 23(11):1325-33. PubMed ID: 8310715 [TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics of the antitumor drug navelbine (5'-noranhydrovinblastine). Rahmani R; Bruno R; Iliadis A; Favre R; Just S; Barbet J; Cano JP Cancer Res; 1987 Nov; 47(21):5796-9. PubMed ID: 3664483 [TBL] [Abstract][Full Text] [Related]
6. Pulmonary distribution of vinorelbine in patients with non-small-cell lung cancer. Levêque D; Quoix E; Dumont P; Massard G; Hentz JG; Charloux A; Jehl F Cancer Chemother Pharmacol; 1993; 33(2):176-8. PubMed ID: 8261579 [TBL] [Abstract][Full Text] [Related]
7. Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinorelbine in mice as determined by high performance liquid chromatography. van Tellingen O; Kuijpers AV; Beijnen JH; Nooijen WJ; Bult A Invest New Drugs; 1993; 11(2-3):141-50. PubMed ID: 8262726 [TBL] [Abstract][Full Text] [Related]
8. Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities. Egorin MJ; Van Echo DA; Whitacre MY; Forrest A; Sigman LM; Engisch KL; Aisner J Cancer Res; 1986 Mar; 46(3):1513-20. PubMed ID: 2935249 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of a new anticancer drug, navelbine, in patients. Comparative study of radioimmunologic and radioactive determination methods. Boré P; Rahmani R; van Cantfort J; Focan C; Cano JP Cancer Chemother Pharmacol; 1989; 23(4):247-51. PubMed ID: 2924381 [TBL] [Abstract][Full Text] [Related]
10. Biliary elimination and pharmacokinetics of vinorelbine in micropigs. Levêque D; Merle-Melet M; Bresler L; Didelot JP; Aymard JP; Wihlm J; Jehl F Cancer Chemother Pharmacol; 1993; 32(6):487-90. PubMed ID: 8258199 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of 9-methoxy-N,N-dimethyl-5-nitropyrazolo [3,4, 5-kl]acridine-2(6H)-propanamine (PZA, PD 115934, NSC 366140) in mice: guidelines for early clinical trials1. Foster BJ; Wiegand RA; LoRusso PM; Baker LH Clin Cancer Res; 1995 Aug; 1(8):831-7. PubMed ID: 9816052 [TBL] [Abstract][Full Text] [Related]
12. Oral administration of [3H]navelbine in patients: comparative pharmacokinetics using radioactive and radioimmunologic determination methods. Rahmani R; Zhou XJ; Boré P; Van Cantfort J; Focan C; Cano JP Anticancer Drugs; 1991 Aug; 2(4):405-10. PubMed ID: 1797198 [TBL] [Abstract][Full Text] [Related]
13. Single- and multiple dose pharmacokinetics of lonidamine in patients suffering from non-small-cell lung cancer. Gatzemeier U; Toomes H; Picollo R; Christoffel V; Lücker PW; Ulmer J Arzneimittelforschung; 1991 Apr; 41(4):436-9. PubMed ID: 1650226 [TBL] [Abstract][Full Text] [Related]
14. HPLC-NMR with severe column overloading: fast-track metabolite identification in urine and bile samples from rat and dog treated with [14C]-ZD6126. Lenz EM; D'Souza RA; Jordan AC; King CD; Smith SM; Phillips PJ; McCormick AD; Roberts DW J Pharm Biomed Anal; 2007 Feb; 43(3):1065-77. PubMed ID: 17030109 [TBL] [Abstract][Full Text] [Related]
15. Plasma pharmacokinetics of vinblastine and the investigational Vinca alkaloid N-(deacetyl-O-4-vinblastoyl-23)-L-ethyl isoleucinate in mice as determined by high-performance liquid chromatography. van Tellingen O; Beijnen JH; Nooijen WJ; Bult A Cancer Res; 1993 May; 53(9):2061-5. PubMed ID: 8481908 [TBL] [Abstract][Full Text] [Related]
16. Concomitant decrease of resistance and modifications of the cytoskeleton after all-trans retinoic acid and phorbol ester treatments in a navelbine-resistant bladder carcinoma cell line. Debal V; Breillout F; Manfait M Anticancer Res; 1997; 17(2A):1147-54. PubMed ID: 9137463 [TBL] [Abstract][Full Text] [Related]
19. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors. Supko JG; Balcerzak SP; Kraut EH Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671 [TBL] [Abstract][Full Text] [Related]
20. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer. Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]